Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Free Cash Flow (2020 - 2025)

Biofrontera has reported Free Cash Flow over the past 6 years, most recently at -$2.4 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$2.4 million for Q4 2025, down 147.08% from a year ago — trailing twelve months through Dec 2025 was -$13.4 million (down 30.37% YoY), and the annual figure for FY2025 was -$13.4 million, down 30.37%.
  • Free Cash Flow for Q4 2025 was -$2.4 million at Biofrontera, up from -$3.8 million in the prior quarter.
  • Over the last five years, Free Cash Flow for BFRIW hit a ceiling of $94000.0 in Q2 2022 and a floor of -$21.0 million in Q4 2021.
  • Median Free Cash Flow over the past 5 years was -$3.4 million (2021), compared with a mean of -$4.6 million.
  • Biggest five-year swings in Free Cash Flow: soared 108.89% in 2022 and later tumbled 11084.04% in 2023.
  • Biofrontera's Free Cash Flow stood at -$21.0 million in 2021, then skyrocketed by 60.6% to -$8.3 million in 2022, then decreased by 7.12% to -$8.9 million in 2023, then soared by 88.98% to -$977000.0 in 2024, then tumbled by 147.08% to -$2.4 million in 2025.
  • The last three reported values for Free Cash Flow were -$2.4 million (Q4 2025), -$3.8 million (Q3 2025), and -$3.1 million (Q2 2025) per Business Quant data.